|
| Status |
Public on Nov 01, 2015 |
| Title |
Oncogenic deregulation of EZH2 as an opportunity for targeted therapy in lung cancer |
| Organism |
Mus musculus |
| Experiment type |
Expression profiling by high throughput sequencing
Genome binding/occupancy profiling by high throughput sequencing
|
| Summary |
This SuperSeries is composed of the SubSeries listed below.
|
| |
|
| Overall design |
Refer to individual Series
|
| |
|
| Citation missing |
Has this study been published? Please login to update or notify GEO. |
| |
| Submission date |
Jun 19, 2015 |
| Last update date |
May 15, 2019 |
| Contact name |
James Bradner |
| E-mail(s) |
bradner_computation@dfci.harvard.edu
|
| Organization name |
Dana-Farber Cancer Institute
|
| Department |
Medical Oncology
|
| Lab |
Bradner Lab
|
| Street address |
450 Brookline
|
| City |
Boston |
| State/province |
MA |
| ZIP/Postal code |
02215 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL19057 |
Illumina NextSeq 500 (Mus musculus) |
|
| Samples (19)
|
|
| This SuperSeries is composed of the following SubSeries: |
| GSE70045 |
Oncogenic deregulation of EZH2 as an opportunity for targeted therapy in lung cancer [ChIP-Seq] |
| GSE70046 |
Oncogenic deregulation of EZH2 as an opportunity for targeted therapy in lung cancer [RNA-Seq] |
|
| Relations |
| BioProject |
PRJNA287533 |
Less...
More...